Article
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
The Journal of infectious diseases - 1 Oct 1996
Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T
Abstract excerpt
Eight zidovudine-experienced subjects received zidovudine and didanosine for 30 weeks followed by 30 weeks of didanosine monotherapy. At study entry, plasma from 4 subjects had human immunodeficiency virus RNA pol T215Y/F mutant and 4 had codon 215 wild type. All 8 subjects had non-syncytium-indu...
Topics
- Acquired Immunodeficiency Syndrome
- Adult
- Anti-HIV Agents
- CD4 Lymphocyte Count
- Codon
- Didanosine
- Drug Therapy, Combination
- HIV Reverse Transcriptase
- Humans
- Male
- Middle Aged
- Mutation
- Phenotype
- RNA, Viral
- Zidovudine